How does Pentapeptide-18 compare to Argireline?

Both reduce wrinkles by limiting muscle contraction, but they work at different stages. Argireline (acetyl hexapeptide-8) inhibits SNARE complex formation, preventing synaptic vesicles from fusing and releasing neurotransmitter. Pentapeptide-18 works further upstream — it mimics enkephalins and binds to opioid receptors on the nerve terminal, closing calcium channels so the release signal never fires in the first place. Because they target different steps in the same cascade, they produce a synergistic effect when combined: manufacturer data shows 5% Leuphasyl alone reduces wrinkle depth by ~11% over 28 days, but combined with Argireline, reductions reach ~25% on average (up to 47% in some subjects).

How does Pentapeptide-18 compare to Botox?

Botox (botulinum toxin) is injected and cleaves SNAP-25, completely blocking acetylcholine release at the injection site — full muscle paralysis. Pentapeptide-18 is applied topically and modulates (not blocks) acetylcholine release by mimicking enkephalins at the presynaptic terminal — partial relaxation without immobilization. Botox is far more potent and requires medical administration; Pentapeptide-18 is gentler, preserves facial expressivity, and is available in over-the-counter skincare products.

What is the optimal concentration for Pentapeptide-18?

Clinical evaluation by Dragomirescu et al. (2014) determined that the minimal effective concentration is 2% applied twice daily, which produced visible wrinkle reduction with no adverse effects. Manufacturer (Lipotec) efficacy data used 5% concentrations. Most commercial cosmeceutical formulations include Pentapeptide-18 at concentrations between 2-5%.

Is Pentapeptide-18 an opioid?

Not in any meaningful pharmacological sense. While it mimics enkephalin structure and binds to opioid receptors on nerve terminals in the skin, it is applied topically at very low concentrations with negligible systemic absorption. It does not cross the blood-brain barrier or produce analgesic, euphoric, or addictive effects. Its opioid receptor activity is localized to modulating neurotransmitter release at the neuromuscular junction.

Pentapeptide-18

A synthetic enkephalin-mimicking pentapeptide that reduces acetylcholine release at the neuromuscular junction, relaxing facial muscles and smoothing expression wrinkles. Reduces wrinkle depth by ~11% alone and up to 25% when combined with Argireline.

PreliminaryModerate Data Beginner-Friendly

What is Pentapeptide-18?

Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide with the sequence Tyr-D-Ala-Gly-Phe-Leu, developed by Lipotec (now Lubrizol) as a cosmeceutical anti-wrinkle ingredient. Its design is based on the natural enkephalin opioid pentapeptides — leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) — with a D-alanine substitution at position 2 that improves enzymatic stability. Like natural enkephalins, it binds to opioid receptors on presynaptic nerve terminals, triggering a G-protein cascade that closes calcium channels and opens potassium channels. This reduces calcium influx, preventing synaptic vesicle fusion and decreasing acetylcholine release across the neuromuscular junction. The result is reduced muscle contraction intensity and softer expression wrinkles — particularly forehead lines and crow's feet. Unlike Argireline (which blocks SNARE complex assembly) or Syn-Ake (which blocks the postsynaptic receptor), Pentapeptide-18 works upstream by mimicking the body's own inhibitory signaling.

Why People Talk About It

Expression wrinkle reduction (forehead, crow's feet)

Preliminary

Synergistic combination with Argireline for enhanced anti-wrinkle effect

Preliminary

Non-injectable alternative to botulinum toxin

Preliminary

Anti-melanogenic potential via D-tyrosine modification

Limited

How It Works

Before your facial muscles contract, a nerve signal triggers the release of acetylcholine — the chemical messenger that tells the muscle to move. Your body naturally has enkephalins, small peptides that can dial down this nerve signaling. Pentapeptide-18 mimics these enkephalins: it binds to receptors on the nerve ending and tells the cell to reduce its activity. With less acetylcholine released, your facial muscles contract less intensely, and the expression wrinkles they create (like forehead lines and crow's feet) gradually soften.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Well-tolerated topically at standard cosmeceutical concentrations (2-5%)No significant adverse effects reported in clinical or safety testingThe 2014 Dragomirescu study found the 2% concentration free of side effects over 60 days

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Topical efficacy depends on skin penetration, which varies by formulation and delivery system
• Most clinical data comes from manufacturer-sponsored studies (Lipotec/Lubrizol)
• Over-the-counter products vary widely in concentration and formulation quality

What We Don't Know

Long-term effects of chronic topical enkephalin receptor modulation on facial nerve signaling are not studied. Whether clinically meaningful presynaptic inhibition occurs through intact skin at cosmeceutical concentrations remains debated — in vitro receptor binding is demonstrated, but in vivo transdermal delivery efficiency is uncertain. Independent clinical replication beyond manufacturer data is limited.

Published Research

6 studies

Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis.

2026 computational study analyzing Pentapeptide-18 interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathways via molecular docking and dynamics simulations.

PreclinicalPMID: 41722287

Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18 — Optimization, Characterization, and Cosmetic Application.

2024 study optimizing Pentapeptide-18 delivery in solid lipid nanoparticles with retinol for enhanced anti-aging cosmetic application.

Formulation StudyPMID: 39337562

D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.

Park et al. (2020) demonstrated that D-tyrosine-modified Pentapeptide-18 reduces melanin content and tyrosinase activity in melanocytes.

PreclinicalPMID: 31937863

The Efficiency and Safety of Leuphasyl — A Botox-Like Peptide.

Dragomirescu et al. (2014) evaluated optimal concentration, safety, and efficacy of Leuphasyl for wrinkle reduction using digital imaging and silicone replicas.

Clinical Study

Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.

Comprehensive review covering Leuphasyl mechanism, synergy with Argireline, and classification among neurotransmitter inhibitor peptides.

Review

Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.

2025 review summarizing Pentapeptide-18 clinical evidence, optimal concentration data, and combination strategies with Argireline.

Review

Mechanism of Action

Pentapeptide-18 (H-Tyr-D-Ala-Gly-Phe-Leu-OH, MW 569.6 g/mol) is a synthetic analog of leucine-enkephalin with a D-alanine substitution at position 2 that confers resistance to aminopeptidase degradation. It functions as an agonist at delta-opioid receptors (DOR) on presynaptic motor nerve terminals. Upon binding, the receptor couples to inhibitory Gi/Go proteins, activating a signaling cascade that closes voltage-gated calcium channels (VGCCs) and opens inwardly rectifying potassium channels (GIRKs). Reduced Ca2+ influx prevents synaptic vesicle docking and fusion with the presynaptic membrane, thereby inhibiting acetylcholine exocytosis across the neuromuscular junction. This presynaptic mechanism is complementary to Argireline's SNARE complex inhibition (also presynaptic but downstream) and Syn-Ake's postsynaptic nicotinic receptor antagonism, enabling multi-target combination strategies. A 2026 computational study (PMID: 41722287) analyzed Pentapeptide-18's interactions with five aging-related signaling pathways — TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB — using FTIR/Raman spectroscopy, DFT calculations, and molecular dynamics simulations, supporting broader anti-aging activity beyond neuromuscular modulation. Additionally, Park et al. (2020) demonstrated that D-tyrosine-containing derivatives of Pentapeptide-18 reduce melanin content and tyrosinase activity in melanocytes by 18-25%, suggesting dual anti-wrinkle and skin-brightening potential (PMID: 31937863).

Evidence Snapshot

Overall Confidence25%

Human Clinical Evidence

Limited. Manufacturer data (Lipotec) from an in vivo study showed 5% Leuphasyl applied twice daily for 28 days reduced wrinkle depth by ~11%, and combination with 5% Argireline achieved ~25% average reduction (up to 47%). Dragomirescu et al. (2014) evaluated 2% Leuphasyl cream applied twice daily for 60 days using digital imaging and silicone replicas, reporting 34.7% wrinkle depth reduction on the forehead and 28.4% around the eyes, with an overall average reduction of 11.31% at lower concentrations over 28 days. A 2024 study incorporated Pentapeptide-18 into solid lipid nanoparticles with retinol, demonstrating stable delivery and anti-aging effects in an 8-week trial (PMID: 39337562). All studies are manufacturer-sponsored or small-scale.

Animal / Preclinical

Limited. Primarily in vitro: enkephalin receptor binding demonstrated in cell-based assays with downstream calcium channel modulation confirmed. Park et al. (2020) showed D-tyrosine-modified Pentapeptide-18 reduced melanin content by 18-25% and tyrosinase activity in MNT-1 melanoma cells and primary melanocytes (PMID: 31937863). A 2026 computational study used molecular docking, dynamics simulations, and ADMET analysis to characterize Pentapeptide-18 interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathway targets (PMID: 41722287).

Mechanistic Rationale

Moderate. The enkephalin-mediated presynaptic inhibition mechanism is pharmacologically well-established for endogenous opioid peptides. The D-Ala2 substitution improving enzymatic stability is a proven strategy from opioid peptide pharmacology. Whether sufficient receptor engagement occurs through topical application at cosmeceutical concentrations to produce clinically meaningful neuromuscular modulation is the central question — the mechanism is sound, but transdermal bioavailability at the target site is uncertain.

Forms & Administration

Pentapeptide-18 is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Standard concentrations range from 2-5% in finished products. Most effective when combined with Argireline (acetyl hexapeptide-8) for synergistic expression line reduction, and sometimes paired with Matrixyl (collagen stimulation) or Syn-Ake (postsynaptic receptor blocking) for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required for cosmeceutical products. Advanced delivery systems such as solid lipid nanoparticles have been explored to improve skin penetration and stability.

Use Cases & Evidence Levels

Expression wrinkle reduction (forehead, crow's feet)

Preliminary30%

Synergistic combination with Argireline for enhanced anti-wrinkle effect

Preliminary30%

Non-injectable alternative to botulinum toxin

Preliminary30%

Anti-melanogenic potential via D-tyrosine modification

Limited15%

Safety Profile

Safety Information

Common Side Effects

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Topical efficacy depends on skin penetration, which varies by formulation and delivery system
• Most clinical data comes from manufacturer-sponsored studies (Lipotec/Lubrizol)
• Over-the-counter products vary widely in concentration and formulation quality

What We Don't Know

Published Research

6 studies

Pentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis.

2026 computational study analyzing Pentapeptide-18 interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathways via molecular docking and dynamics simulations.

PreclinicalPMID: 41722287

Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18 — Optimization, Characterization, and Cosmetic Application.

2024 study optimizing Pentapeptide-18 delivery in solid lipid nanoparticles with retinol for enhanced anti-aging cosmetic application.

Formulation StudyPMID: 39337562

D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.

Park et al. (2020) demonstrated that D-tyrosine-modified Pentapeptide-18 reduces melanin content and tyrosinase activity in melanocytes.

PreclinicalPMID: 31937863

The Efficiency and Safety of Leuphasyl — A Botox-Like Peptide.

Dragomirescu et al. (2014) evaluated optimal concentration, safety, and efficacy of Leuphasyl for wrinkle reduction using digital imaging and silicone replicas.

Clinical Study

Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.

Comprehensive review covering Leuphasyl mechanism, synergy with Argireline, and classification among neurotransmitter inhibitor peptides.

Review

Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.

2025 review summarizing Pentapeptide-18 clinical evidence, optimal concentration data, and combination strategies with Argireline.

Review

Related Peptides

Argireline

ModerateBeginner

A cosmetic peptide that reduces wrinkles by inhibiting neurotransmitter release at the neuromuscular junction, often called 'topical Botox.'

SNAP-8

EmergingBeginner

A cosmetic peptide that reduces the appearance of wrinkles by modulating neuromuscular junction signaling.

Syn-Ake

PreliminaryBeginner

A synthetic tripeptide that mimics Temple Pit Viper venom, blocking muscular acetylcholine receptors to reduce dynamic wrinkles. Often called 'topical Botox' — reduces muscle contractions by 82% in vitro.

Matrixyl

ModerateBeginner

A collagen-stimulating cosmetic peptide that signals skin to produce more collagen and extracellular matrix proteins.

GHK-Cu

ModerateBeginner

A naturally occurring copper-binding peptide with extensive research on skin remodeling, wound healing, and anti-aging.

Palmitoyl Tripeptide-1

ModerateBeginner

A collagen-boosting cosmetic peptide that mimics the body's wound-healing signal to stimulate collagen and elastin production in the skin.

Rigin

PreliminaryBeginner

An immunomodulatory tetrapeptide derived from human IgG, used in cosmeceuticals as Palmitoyl Tetrapeptide-7 to suppress skin inflammation (IL-6) and support anti-aging skin repair.

Quick Facts

Class: Cosmeceutical Peptide
Evidence: Preliminary
Safety: Moderate Data
Updated: Apr 2026
Citations: 6PubMed

Also known as

LeuphasylTyr-D-Ala-Gly-Phe-LeuEnkephalin Mimetic Peptide

Evidence Score

Overall Confidence25%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.